SHFH — what changed in the latest 10-Q
A section-by-section comparison of SHFH's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-14 vs the prior 10-Q · 2025-11-12
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +19 | −13 | ~7 | 30 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 11 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Risk factors, Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-14
Results of Operations for three months ended March 31, 2026 and 2025
For the three months ended March 31, 2026, the Company has generated a revenue of $188,756. The revenue generated was mainly from the retail sales of health supplements and topical creams, amount of $182,278 and provision of physical check-up services, amount of $6,478.
For the three months ended March 31, 2026, the Company has cost of revenues in the amount of $129,688. Cost of retail trading revenue was $129,688, while cost of service revenue was nil.
For the three months ended March 31, 2025, the Company has cost of revenues in the amount of $25,135.
The cost of service revenue was mainly from the medical supplies cost.
Text removed vs the prior filing · source: 10-Q · 2025-11-12
Results of Operations for three and nine months ended September 30, 2025 and for the period ended September 30, 2024
For the three and nine months ended September 30, 2025, the Company generated revenue in the amount of $39,604 and $115,980 respectively. The revenue generated was mainly from the retail sales of health supplements and topical creams.
For the three and nine months ended September 30, 2025, the Company has cost of revenues in the amount of $23,534 and $66,682 respectively.
From July 3, 2024 (Date of Inception) to September 30, 2024, the Company has cost of revenues in the amount of $32,972.
For the three and nine months ended September 30, 2025, the Company had general and administrative expenses in the amount of $63,915 and $128,297 respectively. These were primarily comprised of consultancy fees, professional fees, audit fees, IT fees, rental fees, building management fee, company in…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice